Development of a tissue-culture-based enzyme-immunoassay method for the quantitation of anti-vaccinia-neutralizing antibodies in human sera.
Vaccination with vaccinia virus is carried out in order to induce protection against variola virus, the causative agent of smallpox. Serum titer of vaccinia virus-neutralizing antibodies is considered to be well-correlated with in vivo protection. Plaque reduction neutralization test (PRNT) is the gold standard for detecting and quantifying vaccinia virus-neutralizing antibodies in sera of vaccinees. However, PRNT is time and labor consuming, which does not allow large-scale screening needed for a population survey. A simplified, sensitive, standardized, reproducible and rapid method, neutralization tissue-culture enzyme immunoassay (NTC-EIA) was developed for quantitation of neutralizing antibodies against vaccinia virus. The assay consists of the following steps: neutralization of the virus with serially diluted sera, infection of cells in culture and measurement of residual virus replication using an enzyme immunoassay. The assay can be used for animal (rabbit) or human sera. Titer averages obtained using NTC-EIA were highly correlated (R2=0.9994) to those obtained using PRNT. The assay is carried out in 96-well plates and takes only 2 days to complete. With the appropriate setup, it can be automated fully to allow screening of a large number of sera.
Eyal
Osnat
O
Department of Infectious Diseases, Israel Institute for Biological Research, P.O. Box 19, Ness-Ziona, Israel.
Olshevsky
Udy
U
Lustig
Shlomo
S
Paran
Nir
N
Halevy
Menachem
M
Schneider
Paula
P
Zomber
Gil
G
Fuchs
Pinhas
P
D000914:Antibodies, Viral / Q000097:blood*; D002460:Cell Line; D006801:Humans; D007124:Immunoenzyme Techniques / Q000379:methods*; D009500:Neutralization Tests / Q000379:methods*; D014615:Vaccinia / Q000097:blood*; D012901:Variola virus / Q000276:immunology*
D000914:Antibodies, Viral